Učitavanje...
The promise of CAR T-cell therapy in aggressive B-cell lymphoma
Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for almost four decades until the advent of chimeric antigen receptor (CAR) T-cell therapy. Within the last one year, two anti-CD19 CAR T-cell thera...
Spremljeno u:
| Izdano u: | Best Pract Res Clin Haematol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594830/ https://ncbi.nlm.nih.gov/pubmed/30213399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beha.2018.07.011 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|